DGAP-News: MorphoSys AG / Key word(s): Miscellaneous Planegg/Munich, Germany, March 23, 2017 MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve as Interim CSO
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, today announced that Dr. Marlies Sproll, the Company's long-standing Chief Scientific Officer, will be on temporary leave from her CSO position for family matters as of April 15, 2017. Dr. Sproll will take leave of absence from her function as member of the Executive Board for a period of initially six months. She continues to be a member of the Executive Board and will return to her CSO role as soon as circumstances will allow. The Supervisory Board of MorphoSys AG has named Dr. Markus Enzelberger as Interim Chief Scientific Officer for the duration of Dr. Sproll's absence. Dr. Enzelberger, who currently holds the position of Senior Vice President Discovery Alliances and Technologies, is a chemist by training and has closely worked together with Dr. Sproll for the past 15 years. Dr. Enzelberger will assume the temporary CSO duties effective April 15, 2017. About MorphoSys: HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=XNEPMMSLTB Document title: Media Release 23.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |